Shots:

• The US FDA has granted BTD to Olorofim for the treatment of CNS Valley Fever (coccidioidomycosis)
• The therapy is currently being evaluated in P-IIb study in patients with coccidioidomycosis with proven IFD or probable IA and either refractory disease- resistance- or intolerance to available agents
• The BTD follows the previous BTD that was granted on Nov 11- 2019- for the treatment of invasive mold infections in patients with limited or no treatment options- including aspergillosis refractory or intolerant to currently available therapy- and infections due to Lomentospora prolificans- Scedosporium- and Scopulariopsis species

 ­ Ref: PRNewswire | Image: F2G